Polycythemia Vera Treatment Guidelines

Treatment for polycythemia vera (PV) centers on preventing blood clots and controlling blood counts, with the specific approach depending on whether you fall into the low-risk or high-risk category. Nearly every patient starts with phlebotomy to keep the hematocrit below 45% and low-dose aspirin to reduce clotting events. From there, the picture branches: some people manage well with phlebotomy alone for years, while others need drug therapy to keep their blood counts in check. The treatment landscape has shifted meaningfully in recent years, with interferon-based drugs gaining ground as front-line options alongside hydroxyurea and newer agents entering trials.

What Drives the Disease and How Diagnosis Shapes Treatment

PV is driven by a mutation in the JAK2 gene in about 97% of cases, most commonly the V617F variant. This mutation causes overactivation of a signaling pathway that stimulates excessive production of red blood cells, and often white blood cells and platelets too.¹ Understanding that PV is a JAK2-driven problem is what makes targeted therapies possible, and it also means that JAK2 mutation testing is central to diagnosis.

Current diagnostic criteria, revised by the WHO, use three major criteria: a characteristic bone marrow appearance, a hemoglobin level above 16.5 g/dL (or hematocrit above 49%) in men or above 16 g/dL (hematocrit above 48%) in women, and the presence of a JAK2 mutation. For the rare cases that lack a JAK2 mutation, a low erythropoietin level serves as a minor criterion.² Before anyone starts treatment, confirming true PV matters because secondary causes of high red blood cell counts, like chronic lung disease or living at high altitude, need entirely different management. Measuring erythropoietin is the key first step to distinguish PV from these mimics.³

Risk Stratification Determines How Aggressively You Are Treated

Once PV is confirmed, your doctor assigns you to one of two risk categories. High-risk means you are older than 60 or you have a history of blood clots. Low-risk means neither applies. This simple split drives the single biggest treatment decision: whether you need cytoreductive therapy (drugs that lower blood cell production) on top of phlebotomy and aspirin.⁴

Additional factors modify the picture within those two categories. Cardiovascular risk factors like high blood pressure, diabetes, and smoking further raise the chance of arterial clots, while a higher JAK2 mutation burden and elevated white blood cell counts are tied to greater venous clot risk.⁵ These additional predictors are increasingly being studied in low-risk patients to see whether some of them should be treated more aggressively than the two-tier system suggests.⁶

Hematocrit Below 45 Percent Is the Universal Target

Regardless of risk category, every PV patient is managed with the goal of keeping hematocrit under 45%. The evidence behind this target comes from a landmark trial that compared a strict target of under 45% to a more lenient target of 45-50%. Patients in the lenient group had roughly four times the rate of cardiovascular events and death from cardiovascular causes compared to the strict-control group.⁷ That result made the under-45% target standard across all major guidelines.

Phlebotomy, simply removing a unit of blood at regular intervals, is the fastest way to bring hematocrit down. It works within hours and remains the backbone of early management. However, repeated phlebotomy depletes iron stores, and the resulting iron deficiency is not a minor footnote. Patients frequently develop fatigue, difficulty concentrating, and general lethargy that can be worse than the PV symptoms themselves.⁸ Many patients already have some degree of iron deficiency at the time of diagnosis because the disease itself burns through iron by driving overproduction of red blood cells.

Survey data bear out the burden. Quality of life worsens with higher phlebotomy frequency: patients who need phlebotomies monthly or more often report more sick days, more days spent in bed, and more canceled plans than those who need them less frequently.⁹ This is a major reason why reducing the need for phlebotomy has become a treatment goal in its own right, and why newer drugs that accomplish this are generating so much interest.

Low-Dose Aspirin for Nearly Everyone

Low-dose aspirin is recommended for virtually all PV patients who can tolerate it. A large randomized trial showed that aspirin cut the combined risk of nonfatal heart attack, nonfatal stroke, major vein clots, and cardiovascular death by about 60%, without a significant increase in major bleeding.¹⁰ In practice, most patients take aspirin once daily, though twice-daily dosing is sometimes recommended for those considered at particularly high clotting risk, because the rapid turnover of platelets in PV means a single daily dose may not suppress platelet activity for a full 24 hours.¹¹

Cytoreductive Therapy for High-Risk Patients

When phlebotomy and aspirin are not enough, or when you fall into the high-risk group, the next step is adding a drug to reduce blood cell production. Two main options compete for the front-line spot: hydroxyurea and interferon alfa.

Hydroxyurea

Hydroxyurea has been the workhorse of PV treatment for decades. It is inexpensive, taken as a daily pill, and effective at controlling hematocrit and blood counts in most patients. In a study of 261 patients treated with hydroxyurea for a median of about four and a half years, roughly 90% achieved at least a partial response. But complete response, meaning normalization of all blood counts plus symptom control, was reached in only about a quarter of patients. And hydroxyurea resistance or intolerance developed in about 11% and 13% of patients respectively, which is a significant proportion over a lifetime of treatment. Resistance was tied to a substantially higher risk of death and disease transformation.¹²

One concern that comes up frequently is whether long-term hydroxyurea raises the risk of leukemia. The evidence is debated, but the drug does not appear to carry a strong independent leukemia risk when used alone. The disease itself carries a transformation risk over the long term. Still, this concern is one factor pushing many clinicians toward interferon-based therapy, especially in younger patients who will be on treatment for decades.

Interferon Alfa

Pegylated interferon alfa, and specifically its newer formulation ropeginterferon alfa-2b, has emerged as a front-line alternative to hydroxyurea. Its appeal goes beyond simple blood count control: interferon can actually reduce the burden of the JAK2 mutation in the bone marrow, something hydroxyurea does not reliably do. In a phase 2 trial of pegylated interferon alfa-2a with a median follow-up of 42 months, about 76% of PV patients achieved a complete hematologic response. More strikingly, 18% achieved a complete molecular response, meaning the JAK2 V617F mutation became undetectable.¹³ A reduction in JAK2 allele burden was observed in about 88% of patients receiving pegylated interferon in another study.¹⁴

A meta-analysis of ropeginterferon alfa-2b specifically found a pooled complete hematologic response rate of about 63% at 12 months, with a molecular response in about a quarter of patients. The most common side effects were elevated liver enzymes, flu-like symptoms, and anemia.¹⁵ The liver enzyme elevations are something doctors watch closely, but for most patients the side effects are manageable, and many people find the flu-like symptoms diminish over the first few months.

The potential to actually modify the underlying disease rather than just suppress its output makes interferon uniquely attractive. Guidelines increasingly position ropeginterferon alfa-2b alongside hydroxyurea as a front-line option, particularly for younger patients and those where disease modification is a priority.

When First-Line Treatment Fails

For patients who cannot tolerate or no longer respond to hydroxyurea, ruxolitinib, a JAK1/JAK2 inhibitor, is the established second-line therapy. In the pivotal RESPONSE trial, ruxolitinib achieved hematocrit control in 60% of patients versus 20% on best available therapy, and about half of patients saw at least a 50% reduction in their overall symptom score. Spleen size shrank by at least 35% in 38% of ruxolitinib patients compared to just 1% in the control group.¹⁶

A follow-up trial, RESPONSE-2, looked at patients without enlarged spleens and found that 78% of those who responded at 28 weeks maintained hematocrit control out to 80 weeks.¹⁷ In a phase 2 study, ruxolitinib was even more impressive: 97% of patients achieved hematocrit under 45% without phlebotomy by week 24, and meaningful improvements in itching, night sweats, and bone pain appeared within the first four weeks.¹⁸

Ruxolitinib is particularly valuable for patients with significant symptom burden, especially those with an enlarged spleen, severe itching, or constitutional symptoms like night sweats and weight loss. It does not reduce JAK2 allele burden the way interferon does, so it is more of a symptom-control and blood-count-control agent than a disease-modifying one.

Aquagenic Pruritus and Other Quality-of-Life Challenges

Fatigue is the single most reported symptom in PV. In a large prospective study of over 2,300 patients, about 80% reported fatigue, with roughly 17% rating it as severe. Early satiety and reduced physical activity were also common.¹⁹ About 90% of patients in a separate international survey reported experiencing some MPN-related symptoms, and a substantial proportion reported impairment at work and in daily activities even when classified as low-risk.²⁰

One of the more distinctive PV symptoms is aquagenic pruritus: intense itching triggered by contact with water, often after a shower or bath. In a study of 441 PV patients, only about a quarter received specific treatment for it, usually antihistamines, and those helped only about half the time. Cytoreductive therapy or phlebotomy resolved symptoms in fewer than 6% of patients. JAK2 inhibitors like ruxolitinib appear to be far more effective for this particular symptom.²¹ If you are dealing with water-triggered itching that is seriously disrupting your life, this is a conversation worth having with your hematologist, because it may factor into treatment selection.

Managing Thrombosis When It Happens

Blood clots remain the most dangerous complication of PV, and when one occurs, treatment typically involves anticoagulation on top of the standard PV regimen. In a study of 150 PV and essential thrombocythemia patients who had experienced a clot and were treated with blood-thinning drugs (vitamin K antagonists), the rate of repeat clotting was about 4.5 per 100 patient-years while on anticoagulation, compared to 12 per 100 patient-years after stopping. That roughly three-fold reduction in recurrence supports long-term anticoagulation for anyone with PV who has already had a clot, particularly those with more than one prior event.²²

Pregnancy and PV

PV during pregnancy requires a different treatment toolkit because hydroxyurea is contraindicated due to concerns about harm to the developing baby. The standard approach is phlebotomy to maintain hematocrit in a safe range plus daily low-dose aspirin. For women considered at higher clotting risk, low-molecular-weight heparin is added. If cytoreductive therapy becomes necessary, interferon alfa is the preferred option because it has a more established safety profile in pregnancy than hydroxyurea or ruxolitinib.²³ Pregnancy in PV is manageable, but it requires close coordination between an obstetrician and a hematologist throughout.

Long-Term Risks and Disease Progression

PV is a chronic condition, and while many patients live for decades with it, there are long-term risks that treatment aims to delay. A population-based study found a five-year survival rate of about 80%.²⁴ In a study focused on younger PV patients, no one progressed to acute leukemia or myelofibrosis before the ninth year of follow-up. After that, about 7% developed leukemia and 7% developed myelofibrosis, with a 20-year cumulative risk of roughly 15% and 10% respectively.²⁵ These numbers underline why younger patients in particular may benefit from disease-modifying therapies like interferon that can reduce the JAK2 mutation burden and potentially slow progression.

A nationwide Swedish study covering over 43,000 patient-years confirmed that older age and high white blood cell counts at diagnosis independently predicted thrombosis, bleeding, and overall mortality in PV.²⁶ Keeping white blood cell counts controlled, not just hematocrit, appears to be clinically meaningful.

Hepcidin Mimetics and the Next Wave of Treatment

The newest development in PV treatment is a class of drugs called hepcidin mimetics. Hepcidin is a hormone that regulates iron absorption, and PV patients tend to have relatively low levels of it. Drugs that mimic hepcidin’s action can restrict the iron supply available for red blood cell production, effectively controlling erythrocytosis without traditional myelosuppressive drugs.²⁷

The most advanced of these is rusfertide. In a clinical trial, patients who had needed an average of nearly 9 phlebotomies per year before starting rusfertide dropped to fewer than 1 per year on the drug. Their average peak hematocrit fell from about 50% to about 44.5%. In the randomized portion of the trial, 60% of rusfertide patients maintained their response compared to 17% on placebo.²⁸ Beyond just controlling hematocrit, rusfertide also replenished iron stores and relieved constitutional symptoms, addressing the iron-deficiency problem that phlebotomy creates.²⁹

Other hepcidin pathway agents, including divesiran and sapablursen, are also in development. If this class fulfills its early promise, it could reshape PV management by offering a way to control red blood cell production without the side effects of cytoreductive drugs or the iron depletion of phlebotomy.

Cost and Access Considerations

Newer therapies bring questions about cost. A U.S. cost-effectiveness analysis found that ropeginterferon alfa-2b provided an additional 0.4 quality-adjusted life years over a modeled lifetime at an added cost of roughly $60,000, yielding a cost per quality-adjusted life year of about $142,000.³⁰ An Austrian analysis looking specifically at low-risk PV patients found more favorable numbers, with ropeginterferon reducing costs from thrombosis, myelofibrosis, and leukemia by 12%, 30%, and 16% respectively due to delayed complications, making it cost-effective by Austrian standards.³¹ In Japan, ropeginterferon was found to cost more than hydroxyurea but actually save money compared to ruxolitinib, with better quality-of-life outcomes in both comparisons.³²

For patients, the practical takeaway is that hydroxyurea remains far cheaper as a generic pill, while interferon and ruxolitinib carry significant price tags that may affect out-of-pocket costs depending on insurance. The cost-effectiveness analyses suggest the newer drugs can pay for themselves over time by preventing expensive complications, but that logic works best at the health-system level and does not always translate directly to what you pay at the pharmacy. If cost is a concern, it is worth discussing all available options with your treatment team, because a well-managed hydroxyurea regimen remains a perfectly reasonable choice for many people.

How Incidence Varies and Who Gets PV

PV is uncommon but not rare. In the United States, the average age-adjusted incidence rate is roughly 1.4 to 1.7 new cases per 100,000 people per year, and incidence climbs with age.³³ Men are diagnosed slightly more often than women, though women are certainly not spared. The median age at diagnosis is typically in the mid-60s, but PV can appear at any age, including in young adults, and the treatment approach differs meaningfully for younger patients who face decades of disease management and cumulative risk.